AbbVie to Acquire Apogee for $10.9B to Bolster Pipeline

AbbVie (NYSE: ABBV) has announced the acquisition of Apogee Therapeutics for $10.9 billion in cash, a move designed to strengthen its pipeline in inflammatory and immunology diseases. The deal is expected to close in the first half of 2026.

Deal Details

• Value: $10.9 billion in cash.
• Price: $55 per share, a 35% premium over Apogee's closing price before the announcement.
• Payment Method: All cash.
• Expected Close: First half of 2026.

Rationale

AbbVie aims to bolster its pipeline in immunology and inflammation, reducing reliance on Humira, which faces increasing competition. Apogee has a promising candidate for severe asthma and atopic dermatitis.

Regulatory Challenges

The deal will likely face antitrust review in the US and Europe, but analysts expect approval given limited product overlap.

Impact on Shares

Analysts view the acquisition positively for AbbVie's long-term growth and dividend sustainability, though the cost may pressure near-term cash flows.